China (Mainland)
Premiumsupplier 
INCB024360 CAS NO.914471-09-3
- FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
- Min.Order: 100 Gram
- Payment Terms: L/C
- Available Specifications:
≥98.0%(100-500)Gram≥98.0%(1000-5000)Gram
- Product Details
Keywords
- INCB024360
- INCB 024360;INCB024360;INCB-024360;INCB-24360;indoleaMine-2,3-dioxygenase inhibitor INCB024360;INCB024360/INCB-024360;4-Amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide;
- 914471-09-3
Quick Details
- ProName: INCB024360
- CasNo: 914471-09-3
- Molecular Formula: C9H7ClFN5O2
- Appearance: white crystalline solid
- Application: CAS：914471-09-3； INCB 024360;INCB0243...
- DeliveryTime: 2 months
- PackAge: 100g,500,1kg.....
- Port: shang hai
- ProductionCapacity: 100 Gram/Month
- Purity: 98%
- Storage: Dry seal
- Transportation: shipping
- LimitNum: 100 Gram
Superiority
We are committed to provide excellence in researching, manufacturing and drug discovery process.
Our research team of scientists consists of western-trained Ph.D.s with experience and capabilities in drug R&D methodologies and medicinal chemistry.
Details
IDO-IN-2 is a potent IDO1 inhibitor(IC50=10 nM) with desirable pharmaceutical properties, which is poised to start clinical trials in cancer patients.
IC50 Value: 10 nM [1]
Target: IDO1
in vitro: In cellular assays,IDO-IN-2 selectively inhibits human IDO1 with IC(50) values of approximately 10nM, demonstrating little activity against other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO) [1]. In coculture systems of human allogeneic lymphocytes with dendritic cells (DCs) or tumor cells,IDO-IN-2 inhibition of IDO1 promotes T and natural killer (NK)-cell growth, increases IFN-gamma production, and reduces conversion to regulatory T (T(reg))-like cells. IDO1 induction triggers DC apoptosis, whereas IDO-IN-2 reverses this and increases the number of CD86 (high) DCs, potentially representing a novel mechanism by which IDO1 inhibition activates T cells [1].
in vivo: Consistent with its effects in vitro, administration of IDO-IN-2 to tumor-bearing mice significantly inhibits tumor growth in a lymphocyte-dependent manner [1]. A single dose of IDO-IN-2 or IDO-IN-2 results in efficient and durable suppression of Ido1 activity in the plasma of treated mice and dogs, the former to levels seen in Ido1-deficient mice [2].
Clinical trial: A Phase 2 Study of the IDO Inhibitor IDO-IN-2 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy.